Glaucoma

Ora is able to provide tremendous development value to glaucoma clients in ways that traditional CROs and SMOs simply cannot. We have deep expertise in working with clients to identify and navigate the best development pathway toward product approval.

Experienced Glaucoma Team
led by Aron Shapiro, Vice President, with 13+ years of experience in successfully executing glaucoma programs
International site management
at our 250+ global glaucoma specific site network
Preclinical Glaucoma Capabilities
including ex-vivo mechanistic studies to evaluate conventional outflow facility
Aron Shapiro

Aron Shapiro
VP, Anti-infective, Glaucoma, AI, Retina

Not surprisingly, the United States glaucoma medication market size has grown steadily, totaling nearly $2 billion in annual revenue (IMS (2009)), and is expected to increase even more rapidly as the baby boomer segment of the U.S population ages. Currently, there are five distinct drug classes being used to treat glaucoma. Within these classes of drugs there are additional differences in the mechanisms of action (MOAs) that determine how they lower intraocular pressure (IOP). In addition, there are still other drug classes that researchers believe could greatly improve patient glaucoma therapy in the future.

Ora is an expert in working with clients to identify and navigate the best development pathway toward a product approval. We are able to provide tremendous development value to glaucoma clients in ways that traditional CROs and SMOs simply cannot manage. Ora possesses the expertise and experience to both execute traditional glaucoma study designs or if needed, develop new trial designs that can be used to identify new sub-sets of glaucoma patients and new ways to achieve novel indication goals.

Our capabilities include:

  • Study Design
  • Validated Grading Scales
  • Site Selection and Qualification
  • Multi-Center Site Management
  • Vendor Management
  • Block enrollment at experienced international sites
  • Extensive, active network of Key Opinion Leaders
  • 250+ global glaucoma-specific site network
  • International study capabilities (Latin America, EU, India, Asia)